KALA BIO, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kala Bio (market cap ~$24.6M) entered into an exclusive distribution and reseller agreement with Virotek Inc., effective September 3, 2026, to market and distribute Virotek's ophthalmology genetic testing program (Eyegene and Eyegene PLUS) in the United States. The parties will share Net Profit 50/50 after Virotek recovers cost of goods sold (COGS); specific dollar thresholds and test volumes for the 12-month exclusivity milestone are redacted but material to retention of exclusivity. Kala bears all marketing costs; the 5-year initial term is renewable if exclusivity milestone is met, with Kala granted right of first refusal on related ophthalmology products.
Why this rating
Material commercial deal for a $24.6M company: exclusive distribution of revenue-generating genetic testing program, 50/50 profit split, potential multi-vertical expansion, right of first refusal on related products. Success depends on meeting redacted exclusivity milestones within 12 months.
Price action (we called it positive)
before filing · preread $0.56 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.